Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Prospective Trial After 1st or 2nd Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd or 3rd Time

NCT02917720 is registered in ClinicalTrials.gov with European LeukemiaNet as lead sponsor.

NCT NCT02917720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02917720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Prospective Trial After 1st or 2nd Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd or 3rd Time
Lead sponsor
European LeukemiaNet
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 30, 2016
Completion date
September 30, 2027
Enrollment
75 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia